<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48670">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01976728</url>
  </required_header>
  <id_info>
    <org_study_id>000070</org_study_id>
    <nct_id>NCT01976728</nct_id>
  </id_info>
  <brief_title>LutrePulse Hypogonadotropic Hypogonadism</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic
      hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the
      OmniPod pump versus placebo
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ovulation rate</measure>
    <time_frame>Treatment Days 19 - 25</time_frame>
    <safety_issue>No</safety_issue>
    <description>calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with presence of gestational sac and fetal heart movement on transvaginal ultrasound after a second positive serum pregnancy test</measure>
    <time_frame>2 to 4 weeks after a second positive pregnancy test</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a confirmed positive serum pregnancy test after luteinizing hormone (LH) surge</measure>
    <time_frame>Approximately 14 days after LH surge</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of follicles with a mean diameter ≥14 mm</measure>
    <time_frame>From Day 10 of the treatment period up to approximately 21 full treatment days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dominant follicles with a mean diameter of ≥ 18mm</measure>
    <time_frame>From Day 10 of the treatment period up to approximately 21 full treatment days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum progesterone levels</measure>
    <time_frame>Treatment Days 19, 21, 23, 25, and 27</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean progesterone levels</measure>
    <time_frame>Treatment Days 19, 21, 23, 25, and 27</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in follicle-stimulating hormone (FSH) and LH</measure>
    <time_frame>Treatment Days 1 and 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean serum FSH and LH levels</measure>
    <time_frame>Treatment Days 1 and 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol serum levels</measure>
    <time_frame>At treatment Day 1 and Day 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least 1 post-baseline progesterone level ≥ 10 ng/mL</measure>
    <time_frame>Treatment Days 19 - 25</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Primary Amenorrhea With Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>LutrePulse 10µg/pulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gonadorelin acetate 10µg/pulse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LutrePulse 20µg/pulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gonadorelin acetate 20µg/pulse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin acetate 10µg/pulse</intervention_name>
    <arm_group_label>LutrePulse 10µg/pulse</arm_group_label>
    <other_name>LutrePulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin acetate 20µg/pulse</intervention_name>
    <arm_group_label>LutrePulse 20µg/pulse</arm_group_label>
    <other_name>LutrePulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18-40 years old

          -  Body mass index (BMI) between 18 and 38 kg/m2

          -  Clinical history or recently diagnosed with primary amenorrhea with hypogonadotropic
             hypogonadism

          -  Hormonal values in a centrally analyzed fasting blood sample: FSH &lt;5 IU/L and mean LH
             &lt;5 IU/L

          -  Desire to become pregnant

          -  Discontinued estrogen-progesterone replacement therapy at least 1 month before
             screening

          -  Negative progestin challenge test performed during screening

          -  PAP smear within 24 months of the initial visit

          -  Normal or stable CT scan or MRI scan of the hypothalamic pituitary region

          -  Prolactin and thyroid-stimulating hormone (TSH) within normal clinical laboratory
             limits

          -  Male partner with normal semen analysis, including volume, liquefaction time, sperm
             count, and motility, according to the local laboratory normal criteria, within the
             past year

          -  Normal transvaginal ultrasound at screening with respect to uterus and adnexa
             (presence of both ovaries and tubes, without evidence of clinically significant
             abnormality) and with normal uterine cavity and normal cervix

          -  Tube patency on saline tubal perfusion, hysterosalpingography or laparoscopy on file
             within the past 2 years

        Exclusion Criteria:

          -  Any medical condition that may interfere with the absorption, distribution,
             metabolism, or excretion of the drug

          -  A history of, or currently diagnosed with clinically important cardiovascular,
             pulmonary (e.g. serious corticosteroid-dependent asthma), gastrointestinal, hepatic,
             metabolic, renal, endocrinological (e.g. insulin dependent diabetes mellitus), or
             neurological (e.g. epilepsy, serious migraine, central nervous system (CNS) lesions
             (in cases where hypogonadotropic hypogonadism is secondary to a CNS lesion or its
             treatment) abnormality

          -  A history of adrenal or uncontrolled thyroid disorders, or hyperprolactinemia

          -  Prior treatment cycle with gonadotropins or GnRH within the last 2 months

          -  Known allergy to study drug or its components

          -  Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C

          -  Ovarian enlargement or cyst of unknown etiology

          -  Abnormal gynecological bleeding of undetermined origin

          -  Previous or current hormone-dependent tumor

          -  Known active substance abuse

          -  Planning to undergo in vitro fertilization procedure in the course of a study
             treatment cycle

          -  Currently undergoing treatment with gonadotropin hormones (FSH and LH), psychotropic
             medication, sex hormones, or any other medication known to interfere with normal
             reproductive function or that can affect GnRH secretion (e.g. neuroleptics, dopamine
             antagonists, spironolactone, levodopa, phenothiazine, digoxin)

          -  Ongoing pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Watching Over Mothers &amp; Babies</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Health UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reproductive Associates of Delaware</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Fertility Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Medicine</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Reproductive Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fertility Centers of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center-REI</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University Physicians Group</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University, Center for Menopause hormonal disorders and women's health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Reproductive Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UH Case Medical Center, MacDonald Clinical Trials</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio Reproductive Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center, Abington IVF &amp; Genetics, L.P.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abington Reproductive Medicine, PC</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Main Line Fertility Center</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State MS Hershey Medical Center, Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fertility Associates of Memphis PLLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Assisted Reproduction</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Fertility Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center of Reproductive Medicine</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amenorrhea</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
